- ISIN
- NL0010696654
- CUSIP
- 001069665
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 20, 2007
Highlights
- Market Cap
- $2.79B
- Enterprise Value
- $2.71B
- EPS (TTM)
- -$3.58
- Total Revenue (TTM)
- $18.09M
- Gross Profit (TTM)
- $13.42M
- EBITDA (TTM)
- -$164.53M
- Year Range
- $8.73 - $71.50
- Target Price
- $33.63
- ROA (TTM)
- -26.82%
- ROE (TTM)
- -139.86%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
QURE Performance Chart
uniQure N.V. (QURE) is up 85.5% since the beginning of the year. At $44 per share, QURE is trading 37.9% below its 52-week high of $72. Investors who bought $1,000 worth of QURE shares 5 years ago would now be looking at an investment worth $1,481.
Loading charts...
Returns By Period
uniQure N.V. (QURE) has returned 85.50% so far this year and 212.39% over the past 12 months. Looking at the last ten years, QURE has achieved an annualized return of 19.64%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.
uniQure N.V.
- 1D
- -4.10%
- 1M
- 83.51%
- YTD
- 85.50%
- 6M
- 77.70%
- 1Y
- 212.39%
- 3Y*
- 57.09%
- 5Y*
- 8.17%
- 10Y*
- 19.64%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
QURE Monthly Returns History
Based on dividend-adjusted daily data since Feb 5, 2014, QURE's average daily return is +0.22%, while the average monthly return is +4.29%. At this rate, an investment would double in approximately 1.4 years.
Historically, 43% of months were positive and 57% were negative. The best month was Sep 2025 with a return of +257.4%, while the worst month was Nov 2025 at -59.4%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 11 months.
On a daily basis, QURE closed higher 47% of trading days. The best single day was Sep 24, 2025 with a return of +247.7%, while the worst single day was Nov 3, 2025 at -49.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.06% | -31.21% | 4.61% | 22.02% | 43.01% | 55.59% | 85.50% | ||||||
| 2025 | -10.87% | -16.45% | -19.39% | 39.25% | -1.96% | -3.66% | -0.14% | 17.31% | 257.44% | 15.97% | -59.36% | -13.01% | 35.50% |
| 2024 | -17.87% | 3.42% | -9.57% | -15.19% | 12.24% | -9.49% | 70.98% | -23.63% | -15.73% | 16.02% | 4.37% | 195.81% | 160.86% |
| 2023 | -6.26% | -1.36% | -3.91% | -3.62% | -0.62% | -40.59% | -9.51% | -16.01% | -22.96% | -15.05% | 18.95% | -0.15% | -70.14% |
| 2022 | -12.97% | -5.87% | 6.36% | -17.32% | -3.88% | 29.81% | 36.00% | -22.92% | -3.99% | -0.75% | 42.11% | -14.32% | 9.31% |
| 2021 | -1.99% | 3.64% | -8.20% | -4.21% | 7.62% | -11.32% | -5.81% | -0.03% | 10.38% | -4.81% | -8.60% | -25.53% | -42.60% |
Benchmark Metrics
uniQure N.V. has an annualized alpha of 49.70%, beta of 1.15, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since February 05, 2014.
- This stock participated in 94.45% of S&P 500 Index downside but only 78.01% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 49.70%
- Beta
- 1.15
- R²
- 0.03
- Upside Capture
- 78.01%
- Downside Capture
- 94.45%
Return for Risk
Risk / Return Rank
QURE ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for uniQure N.V. (QURE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| QURE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.28 | ||
| Sortino ratioReturn per unit of downside risk | +1.19 | ||
| Omega ratioGain probability vs. loss probability | 1.59 | 1.37 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 2.45 | 2.78 | -0.33 |
| Martin ratioReturn relative to average drawdown | 3.95 | 12.44 | -8.49 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the uniQure N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the uniQure N.V. was 95.40%, occurring on Jul 8, 2024. The portfolio has not yet recovered.
The current uniQure N.V. drawdown is 45.99%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -95.40%Jul 2024 | 5y 16d | — | 7y 1dJun 2019 - now |
2017 bear market2017 | -85.67%May 2017 | 2y 1mo | 1y 15d | 3y 1moApr 2015 - May 2018 |
2014 bear market2014 | -52.19%May 2014 | 2mo 23d | 7mo 23d | 10mo 16dFeb 2014 - Jan 2015 |
Rate-hike selloffLate 2018 | -47.08%Nov 2018 | 2mo 10d | 3mo 13d | 5mo 23dSep 2018 - Feb 2019 |
2018 bear market2018 | -25.51%Jul 2018 | 1mo 9d | 29d | 2mo 8dJun 2018 - Aug 2018 |
Drawdown Indicators
| QURE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.40% | -56.78% | -38.62% |
Max Drawdown (1Y)Largest decline over 1 year | -87.21% | -9.10% | -78.11% |
Max Drawdown (3Y)Largest decline over 3 years | -87.21% | -18.90% | -68.31% |
Max Drawdown (5Y)Largest decline over 5 years | -90.11% | -25.43% | -64.68% |
Max Drawdown (10Y)Largest decline over 10 years | -95.40% | -33.92% | -61.48% |
Current DrawdownCurrent decline from peak | -45.99% | -1.80% | -44.19% |
Average DrawdownAverage peak-to-trough decline | -56.60% | -10.71% | -45.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.03% | 2.03% | +52.00% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of uniQure N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how uniQure N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for QURE relative to other companies in the Biotechnology industry. Currently, QURE has a P/S ratio of 143.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for QURE in comparison with other companies in the Biotechnology industry. Currently, QURE has a P/B value of 18.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with QURE
Add uniQure N.V. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with QURE